|
|
News Breaks | | | | December 9, 2012 | | 13:52 EDT |  | BMY, PFE | ELIQUIS demonstrates superiority in prevention of recurrent VTE
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced the results of the Phase 3 AMPLIFY-EXT trial, which evaluated treatment with ELIQUIS (apixaban) over a one-year period compared to placebo for the prevention of recurrent venous thromboembolism, VTE, in 2,486 patients who had already completed 6 to 12 months of anticoagulation treatment for VTE, including deep vein thrombosis, DVT, or pulmonary embolism, PE. In the trial, extended treatment with ELIQUIS 2.5 mg and 5 mg twice daily, demonstrated superiority versus placebo in the reduction of the composite endpoint of symptomatic, recurrent VTE and death from any cause (11.6% in the placebo group, compared with 3.8% and 4.2% in the ELIQUIS 2.5 mg and 5 mg groups, respectively, P<0.001), the primary efficacy outcome of the trial. | |
|
News For BMY;PFE From The Last 14 Days Check below for free stories on BMY;PFE the last two weeks. |
|
|
| June 12, 2013 | | 08:02 EDT | | PFE | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
 Subscribe for More Information | | | June 11, 2013 | | 18:09 EDT | | BMY | Orencia trial data shows efficacy rate comparable to Humira
Bristol-Myers announced the results of year two data from AMPLE, a trial of 646 patients comparing the subcutaneous formulation of Orencia, or abatacept, vs. Humira, or adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism annual congress and highlighted during a congress press conference. AMPLE met its primary endpoint as measured by non-inferiority of ACR20 at year one. The Orenica regimen achieved comparable rates of efficacy vs. the Humira regimen, or 64.8% vs. 63.4%, respectively. Onset of response was also generally similar for the two groups. Year two of the study remained investigator-blinded. At year two, the Orencia regimen achieved the same rate of efficacy as the Humira regimen based on ACR20. | | | 16:00 EDT |  | PFE | Options Update; June 11, 2013
Subscribe for More Information | | | 15:15 EDT | | PFE | Pfizer June volatility at one-year high
Subscribe for More Information | | | 08:01 EDT |  | BMY | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information | | | 07:42 EDT | | PFE | Boston Biotech Conferences to host a conference
Subscribe for More Information | | | June 10, 2013 | | 07:40 EDT | | PFE | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | | 07:20 EDT | | PFE | Biomed to host a conference
Subscribe for More Information | | | June 7, 2013 | | 13:49 EDT | | BMY | Bristol-Myers volatility elevated as shares pullback from 11-year high
Subscribe for More Information | | | June 6, 2013 | | 11:04 EDT | | BMY | Bristol-Myers says Health Canada expands Abilify indications
Abilify has received an additional approval from Health Canada as an adjunct, or add-on, treatment to antidepressants for the treatment of major depressive disorder in adults who had an inadequate response to prior antidepressant treatments during the current episode. | | |
|
|
|
|
|
|
